Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.12) by 33.33 percent. This is a 60 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $128.000 thousand which missed the analyst consensus estimate of $4.400 million by 97.09 percent.